EQ Stock Price, Equillium Inc Quote, Chart

Market Summary

USD1.56+0.10

Market Closed

6.85%

EQ Stock Price

View Fullscreen

EQ RSI Chart

EQ Valuation

Market Cap

55.0M

Price/Earnings (Trailing)

-4.12

Price/Sales (Trailing)

1.52

EV/EBITDA

-2.62

Price/Free Cashflow

-2.52

EQ Price/Sales (Trailing)

EQ Profitability

EBT Margin

-35.35%

Return on Equity

-59.08%

Return on Assets

-26.39%

Free Cashflow Yield

-39.7%

EQ Fundamentals

EQ Revenue

Revenue (TTM)

36.1M

Rev. Growth (Qtr)

3.84%

EQ Earnings

Earnings (TTM)

-13.3M

Earnings Growth (Yr)

-184.46%

Earnings Growth (Qtr)

36.87%

Breaking Down EQ Revenue

Last 7 days

-13.8%

Last 30 days

-28.4%

Last 90 days

85.7%

Trailing 12 Months

178.6%

How does EQ drawdown profile look like?

EQ Financial Health

Current Ratio

1.79

EQ Investor Care

Shares Dilution (1Y)

2.44%

Diluted EPS (TTM)

-0.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	20.8M	25.9M	31.0M	36.1M
2022	0	0	0	15.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Equillium Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 08, 2023	rothman joel	acquired	5,106	0.58	8,804	chief development officer
Dec 08, 2023	zedelmayer christine	acquired	5,106	0.58	8,804	sr. vice president and coo
Dec 08, 2023	keyes jason a	acquired	5,106	0.58	8,805	chief financial officer
Jun 09, 2023	rothman joel	acquired	8,400	0.56	15,000	chief development officer
Jun 09, 2023	zedelmayer christine	acquired	8,400	0.56	15,000	sr. vice president and coo
Jun 09, 2023	keyes jason a	acquired	8,400	0.56	15,000	chief financial officer
Dec 09, 2022	rothman joel	acquired	4,546	1.19	3,821	chief development officer
Dec 09, 2022	keyes jason a	acquired	5,288	1.19	4,444	chief financial officer
Aug 29, 2022	keyes jason a	sold	-19,810	2.83	-7,000	chief financial officer
Jun 10, 2022	zedelmayer christine	acquired	16,711	1.85	9,033	sr. vice president and coo

Which funds bought or sold EQ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	reduced	-75.00	-14,000	58,000	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	11,000	11,000	-%
Apr 11, 2024	Capital CS Group, LLC	sold off	-100	-13,737	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-14,228	605,100	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	8,705	8,705	-%
Feb 14, 2024	TANG CAPITAL MANAGEMENT LLC	unchanged	-	-6,800	289,200	0.03%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-956	40,647	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-3.00	145	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	9.00	9.00	-%

Are Funds Buying or Selling EQ?

Are funds buying EQ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EQ

No. of Funds

Unveiling Equillium Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 19, 2024	takeda pharmaceutical co ltd	5.2%	1,842,977	SC 13G
Mar 03, 2023	victory capital management inc	3.93%	1,352,210	SC 13G/A
Jan 31, 2023	victory capital management inc	12.20%	4,192,654	SC 13G/A
Feb 14, 2022	decheng capital management iii (cayman), llc	15.13%	4,447,308	SC 13G
Feb 01, 2022	victory capital management inc	14.04%	4,125,667	SC 13G/A
Feb 16, 2021	decheng capital global life sciences fund iv, l.p.	14.7%	4,271,423	SC 13D
Feb 03, 2021	victory capital management inc	11.32%	2,798,132	SC 13G/A
Feb 14, 2020	partner fund management, l.p.	0%	6	SC 13G/A
Jan 29, 2020	victory capital management inc	12.86%	2,233,724	SC 13G/A

Recent SEC filings of Equillium Inc

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	DEFA14A	DEFA14A
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	ARS	ARS
Apr 01, 2024	PRE 14A	PRE 14A
Apr 01, 2024	8-K	Current Report
Mar 25, 2024	S-8	Employee Benefits Plan
Mar 25, 2024	8-K	Current Report
Mar 25, 2024	10-K	Annual Report
Mar 08, 2024	8-K	Current Report
Mar 08, 2024	3	Insider Trading

Peers (Alternatives to Equillium Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Equillium Inc News

Latest updates

Equillium Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Revenue	3.8%	9,211,000	8,870,000	9,124,000	8,879,000	-
Operating Expenses	-0.7%	12,411,000	12,493,000	12,715,000	12,987,000	13,717,000
S&GA Expenses	-8.3%	3,227,500	3,519,000	3,105,000	3,715,000	5,192,000
EBITDA Margin	-54.1%	-0.34	-0.22	-0.65	-1.33	-3.89
Interest Expenses	-	-	-	259,000	232,000	271,500
Income Taxes	-100.8%	-4,000	496,000	8,000	100,000	-
Earnings Before Taxes	27.6%	-2,326,000	-3,214,000	-3,335,000	-3,880,000	2,773,000
EBT Margin	-43.1%	-0.35	-0.25	-0.70	-1.39	-3.96
Net Income	36.9%	-2,342,000	-3,710,000	-3,343,000	-3,940,000	2,773,000
Net Income Margin	-39.4%	-0.37	-0.27	-0.70	-1.39	-3.96
Free Cashflow	-Infinity%	-5,699,000	-	-6,217,000	-7,997,000	27,723,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.5%	51.00	55.00	59.00	72.00	78.00	49.00	62.00	74.00	85.00	92.00	100	107	85.00	92.00	44.00	50.00	56.00	63.00	58.00	63.00	67.00
Current Assets	-8.5%	49.00	54.00	57.00	70.00	77.00	47.00	60.00	72.00	83.00	92.00	100	107	85.00	92.00	44.00	50.00	55.00	63.00	58.00	63.00	67.00
Cash Equivalents	-32.5%	23.00	34.00	26.00	25.00	59.00	26.00	24.00	26.00	50.00	77.00	74.00	51.00	24.00	49.00	24.00	21.00	13.00	28.00	23.00	21.00	29.00
Net PPE	0.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-10.2%	28.00	31.00	32.00	43.00	46.00	20.00	22.00	22.00	19.00	17.00	15.00	15.00	16.00	14.00	13.00	14.00	14.00	14.00	4.00	3.00	2.00
Current Liabilities	-2.2%	28.00	28.00	25.00	32.00	32.00	15.00	15.00	13.00	9.00	8.00	5.00	7.00	7.00	5.00	3.00	4.00	4.00	4.00	4.00	3.00	2.00
Shareholder's Equity	-6.4%	23.00	24.00	27.00	29.00	32.00	28.00	40.00	53.00	67.00	76.00	85.00	92.00	70.00	78.00	31.00	36.00	42.00	49.00	54.00	59.00	65.00
Retained Earnings	-1.3%	-185	-183	-179	-176	-172	-175	-161	-147	-109	-99.36	-89.07	-79.92	-70.92	-62.01	-55.41	-48.95	-41.11	-33.54	-27.53	-21.46	-15.51
Additional Paid-In Capital	0.5%	208	207	206	205	204	203	202	200	177	175	174	172	141	140	86.00	85.00	83.00	82.00	82.00	81.00	80.00
Shares Outstanding	0.4%	35.00	35.00	35.00	34.00	34.00	34.00	33.00	34.00	29.00	29.00	29.00	27.00	25.00	-	-	-	-	-	-	-	-
Float	-	-	-	16.00	-	-	-	43.00	-	-	-	95.00	-	-	-	19.00	-	-	-	34.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-196.7%	-5,664	-1,909	-6,215	-7,995	27,725	-13,065	-11,259	-12,134	-10,133	-7,010	-6,994	-7,944	-8,253	-4,921	-5,080	-6,370	-9,033	-4,696	-4,756	-4,464	-3,826
Share Based Compensation	6.8%	1,046	979	934	1,038	1,052	1,189	1,302	1,298	1,152	1,150	1,064	1,044	833	847	1,350	787	592	633	581	446	-
Cashflow From Investing	-150.7%	-5,566	10,985	15,000	-25,181	6,978	15,000	8,691	-11,985	-16,889	10,468	28,967	4,860	-17,036	-23,016	8,455	13,005	-5,330	-225	6,040	-2,651	-37,409
Cashflow From Financing	130.4%	79.00	-260	-7,618	-1,429	-1,356	-	-	-	225	174	698	29,964	11.00	53,063	96.00	775	-105	-	-	-	64,762
Buy Backs	-100.0%	-	260	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EQ Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 36,084,000	$ 15,759,000
Operating expenses:
Research and development	37,039,000	37,547,000
Acquired in-process research and development	0	23,049,000
General and administrative	13,567,000	17,239,000
Total operating expenses	50,606,000	77,835,000
Loss from operations	(14,522,000)	(62,076,000)
Other income (expense), net:
Interest expense	(491,000)	(1,053,000)
Interest income	2,334,000	420,000
Other (expense) income, net	(76,000)	281,000
Total other income (expense), net	1,767,000	(352,000)
Net loss before income tax expense	(12,755,000)	(62,428,000)
Income tax expense	580,000	0
Net loss	(13,335,000)	(62,428,000)
Other comprehensive income, net:
Unrealized gain (loss) on available-for-sale securities, net	108,000	(38,000)
Foreign currency translation (loss) gain	(44,000)	252,000
Total other comprehensive income, net	64,000	214,000
Comprehensive loss	$ (13,271,000)	$ (62,214,000)
Net loss per share, basic	$ (0.38)	$ (1.85)
Net loss per share, diluted	$ (0.38)	$ (1.85)
Weighted-average number of common shares outstanding, basic	34,726,384	33,727,945
Weighted-average number of common shares outstanding, diluted	34,726,384	33,727,945

EQ Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 23,216	$ 59,107
Short-term investments	17,650	11,916
Accounts receivable	3,735	2,838
Prepaid expenses and other current assets	4,748	2,874
Total current assets	49,349	76,735
Operating lease right-of-use assets	796	1,191
Property and equipment, net	315	391
Other assets	70	104
Total assets	50,530	78,421
Current liabilities:
Accounts payable	4,707	3,977
Accrued expenses	6,697	7,239
Current portion of deferred revenue	15,729	14,700
Current portion of notes payable		5,714
Current portion of operating lease liabilities	440	408
Total current liabilities	27,573	32,038
Long-term notes payable		3,239
Long-term deferred revenue		10,378
Long-term operating lease liabilities	384	824
Total liabilities	27,957	46,479
Commitments and contingencies
Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2023 and 2022; 35,254,752 and 34,414,149 shares issued and outstanding as of December 31, 2023 and 2022, respectively	3	3
Additional paid-in capital	208,170	204,268
Accumulated other comprehensive income	140	76
Accumulated deficit	(185,740)	(172,405)
Total stockholders' equity	22,573	31,942
Total liabilities and stockholders' equity	$ 50,530	$ 78,421

About Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.

CEO	Mr. Bruce D. Steel C.F.A.
WEBSITE	https://equilliumbio.com
INDUSTRY	Biotechnology
EMPLOYEES	47

Equillium Inc Frequently Asked Questions

What is the ticker symbol for Equillium Inc? What does EQ stand for in stocks?

EQ is the stock ticker symbol of Equillium Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Equillium Inc (EQ)?

As of Thu May 02 2024, market cap of Equillium Inc is 55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EQ stock?

You can check EQ's fair value in chart for subscribers.

What is the fair value of EQ stock?

You can check EQ's fair value in chart for subscribers. The fair value of Equillium Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Equillium Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EQ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Equillium Inc a good stock to buy?

The fair value guage provides a quick view whether EQ is over valued or under valued. Whether Equillium Inc is cheap or expensive depends on the assumptions which impact Equillium Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EQ.

What is Equillium Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, EQ's PE ratio (Price to Earnings) is -4.12 and Price to Sales (PS) ratio is 1.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EQ PE ratio will change depending on the future growth rate expectations of investors.